Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Oscillatory shear potentiates latent TGF-β1 activation more than steady shear as demonstrated by a novel force generator.

Kouzbari K, Hossan MR, Arrizabalaga JH, Varshney R, Simmons AD, Gostynska S, Nollert MU, Ahamed J.

Sci Rep. 2019 Apr 15;9(1):6065. doi: 10.1038/s41598-019-42302-x.

2.

Coculture of Endothelial Cells with Human Pluripotent Stem Cell-Derived Cardiac Progenitors Reveals a Differentiation Stage-Specific Enhancement of Cardiomyocyte Maturation.

Dunn KK, Reichardt IM, Simmons AD, Jin G, Floy ME, Hoon KM, Palecek SP.

Biotechnol J. 2019 Aug;14(8):e1800725. doi: 10.1002/biot.201800725. Epub 2019 May 14.

3.

Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer.

Shah KN, Bhatt R, Rotow J, Rohrberg J, Olivas V, Wang VE, Hemmati G, Martins MM, Maynard A, Kuhn J, Galeas J, Donnella HJ, Kaushik S, Ku A, Dumont S, Krings G, Haringsma HJ, Robillard L, Simmons AD, Harding TC, McCormick F, Goga A, Blakely CM, Bivona TG, Bandyopadhyay S.

Nat Med. 2019 Jan;25(1):111-118. doi: 10.1038/s41591-018-0264-7. Epub 2018 Nov 26.

4.

Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor.

Helman E, Nguyen M, Karlovich CA, Despain D, Choquette AK, Spira AI, Yu HA, Camidge DR, Harding TC, Lanman RB, Simmons AD.

Clin Lung Cancer. 2018 Nov;19(6):518-530.e7. doi: 10.1016/j.cllc.2018.07.008. Epub 2018 Aug 7.

5.

A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated with PARP Inhibitor Resistance.

Hu HM, Zhao X, Kaushik S, Robillard L, Barthelet A, Lin KK, Shah KN, Simmons AD, Raponi M, Harding TC, Bandyopadhyay S.

Cell Rep. 2018 Apr 17;23(3):918-929. doi: 10.1016/j.celrep.2018.03.093.

6.

Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.

Blakely CM, Watkins TBK, Wu W, Gini B, Chabon JJ, McCoach CE, McGranahan N, Wilson GA, Birkbak NJ, Olivas VR, Rotow J, Maynard A, Wang V, Gubens MA, Banks KC, Lanman RB, Caulin AF, St John J, Cordero AR, Giannikopoulos P, Simmons AD, Mack PC, Gandara DR, Husain H, Doebele RC, Riess JW, Diehn M, Swanton C, Bivona TG.

Nat Genet. 2017 Dec;49(12):1693-1704. doi: 10.1038/ng.3990. Epub 2017 Nov 6.

7.

Monitoring Bone Tissue Engineered (BTE) Constructs Based on the Shifting Metabolism of Differentiating Stem Cells.

Simmons AD, Sikavitsas VI.

Ann Biomed Eng. 2018 Jan;46(1):37-47. doi: 10.1007/s10439-017-1937-y. Epub 2017 Oct 11.

PMID:
29022110
8.

Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.

Kondrashova O, Nguyen M, Shield-Artin K, Tinker AV, Teng NNH, Harrell MI, Kuiper MJ, Ho GY, Barker H, Jasin M, Prakash R, Kass EM, Sullivan MR, Brunette GJ, Bernstein KA, Coleman RL, Floquet A, Friedlander M, Kichenadasse G, O'Malley DM, Oza A, Sun J, Robillard L, Maloney L, Bowtell D, Giordano H, Wakefield MJ, Kaufmann SH, Simmons AD, Harding TC, Raponi M, McNeish IA, Swisher EM, Lin KK, Scott CL; AOCS Study Group.

Cancer Discov. 2017 Sep;7(9):984-998. doi: 10.1158/2159-8290.CD-17-0419. Epub 2017 Jun 6.

9.

Inactivation of Capicua drives cancer metastasis.

Okimoto RA, Breitenbuecher F, Olivas VR, Wu W, Gini B, Hofree M, Asthana S, Hrustanovic G, Flanagan J, Tulpule A, Blakely CM, Haringsma HJ, Simmons AD, Gowen K, Suh J, Miller VA, Ali S, Schuler M, Bivona TG.

Nat Genet. 2017 Jan;49(1):87-96. doi: 10.1038/ng.3728. Epub 2016 Nov 21.

10.

Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.

Chabon JJ, Simmons AD, Lovejoy AF, Esfahani MS, Newman AM, Haringsma HJ, Kurtz DM, Stehr H, Scherer F, Karlovich CA, Harding TC, Durkin KA, Otterson GA, Thomas Purcell W, Ross Camidge D, Goldman JW, Sequist LV, Piotrowska Z, Wakelee HA, Neal JW, Alizadeh AA, Diehn M.

Nat Commun. 2016 Nov 14;7:13513. doi: 10.1038/ncomms13513. No abstract available.

11.

Sensing metabolites for the monitoring of tissue engineered construct cellularity in perfusion bioreactors.

Simmons AD, Williams C 3rd, Degoix A, Sikavitsas VI.

Biosens Bioelectron. 2017 Apr 15;90:443-449. doi: 10.1016/j.bios.2016.09.094. Epub 2016 Sep 30.

PMID:
27825527
12.

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.

Chabon JJ, Simmons AD, Lovejoy AF, Esfahani MS, Newman AM, Haringsma HJ, Kurtz DM, Stehr H, Scherer F, Karlovich CA, Harding TC, Durkin KA, Otterson GA, Purcell WT, Camidge DR, Goldman JW, Sequist LV, Piotrowska Z, Wakelee HA, Neal JW, Alizadeh AA, Diehn M.

Nat Commun. 2016 Jun 10;7:11815. doi: 10.1038/ncomms11815. Erratum in: Nat Commun. 2016 Nov 14;7:13513.

13.

Comparative Genomic Analyses of the Human NPHP1 Locus Reveal Complex Genomic Architecture and Its Regional Evolution in Primates.

Yuan B, Liu P, Gupta A, Beck CR, Tejomurtula A, Campbell IM, Gambin T, Simmons AD, Withers MA, Harris RA, Rogers J, Schwartz DC, Lupski JR.

PLoS Genet. 2015 Dec 7;11(12):e1005686. doi: 10.1371/journal.pgen.1005686. eCollection 2015 Dec.

14.

Preclinical Efficacy and Safety Assessment of an Antibody-Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma.

Nguyen M, Miyakawa S, Kato J, Mori T, Arai T, Armanini M, Gelmon K, Yerushalmi R, Leung S, Gao D, Landes G, Haak-Frendscho M, Elias K, Simmons AD.

Clin Cancer Res. 2015 Dec 15;21(24):5552-62. doi: 10.1158/1078-0432.CCR-15-0468. Epub 2015 Aug 3.

15.

Using a PyMOL activity to reinforce the connection between genotype and phenotype in an undergraduate genetics laboratory.

Simmons AD, Nguyen TK, Follis JL, Ribes-Zamora A.

PLoS One. 2014 Dec 2;9(12):e114257. doi: 10.1371/journal.pone.0114257. eCollection 2014.

16.

In vitro and in vivo characterization of irreversible mutant-selective EGFR inhibitors that are wild-type sparing.

Tjin Tham Sjin R, Lee K, Walter AO, Dubrovskiy A, Sheets M, Martin TS, Labenski MT, Zhu Z, Tester R, Karp R, Medikonda A, Chaturvedi P, Ren Y, Haringsma H, Etter J, Raponi M, Simmons AD, Harding TC, Niu D, Nacht M, Westlin WF, Petter RC, Allen A, Singh J.

Mol Cancer Ther. 2014 Jun;13(6):1468-79. doi: 10.1158/1535-7163.MCT-13-0966. Epub 2014 Apr 10.

17.

Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.

Walter AO, Sjin RT, Haringsma HJ, Ohashi K, Sun J, Lee K, Dubrovskiy A, Labenski M, Zhu Z, Wang Z, Sheets M, St Martin T, Karp R, van Kalken D, Chaturvedi P, Niu D, Nacht M, Petter RC, Westlin W, Lin K, Jaw-Tsai S, Raponi M, Van Dyke T, Etter J, Weaver Z, Pao W, Singh J, Simmons AD, Harding TC, Allen A.

Cancer Discov. 2013 Dec;3(12):1404-15. doi: 10.1158/2159-8290.CD-13-0314. Epub 2013 Sep 24.

18.

What have studies of genomic disorders taught us about our genome?

Simmons AD, Carvalho CM, Lupski JR.

Methods Mol Biol. 2012;838:1-27. doi: 10.1007/978-1-61779-507-7_1.

PMID:
22228005
19.

Copy number gain at Xp22.31 includes complex duplication rearrangements and recurrent triplications.

Liu P, Erez A, Nagamani SC, Bi W, Carvalho CM, Simmons AD, Wiszniewska J, Fang P, Eng PA, Cooper ML, Sutton VR, Roeder ER, Bodensteiner JB, Delgado MR, Prakash SK, Belmont JW, Stankiewicz P, Berg JS, Shinawi M, Patel A, Cheung SW, Lupski JR.

Hum Mol Genet. 2011 May 15;20(10):1975-88. doi: 10.1093/hmg/ddr078. Epub 2011 Feb 25.

20.

Implementation of a Service-learning Module in Medical Microbiology and Cell Biology Classes at an Undergraduate Liberal Arts University.

Larios-Sanz M, Simmons AD, Bagnall RA, Rosell RC.

J Microbiol Biol Educ. 2011 May 19;12(1):29-37. doi: 10.1128/jmbe.v12i1.274. Print 2011.

21.

Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity.

Simmons AD, Moskalenko M, Creson J, Fang J, Yi S, VanRoey MJ, Allison JP, Jooss K.

Cancer Immunol Immunother. 2008 Aug;57(8):1263-70. doi: 10.1007/s00262-008-0451-3. Epub 2008 Jan 31.

PMID:
18236040
22.

Admixture estimates based on ABO, Rh and nine STRs in two Venezuelan regions.

Simmons AD, Rodriguez-Arroyo G, Rodriguez-Larralde A.

Ann Hum Biol. 2007 Jan-Feb;34(1):56-67.

PMID:
17536755
23.

GM-CSF-secreting cancer immunotherapies: preclinical analysis of the mechanism of action.

Simmons AD, Li B, Gonzalez-Edick M, Lin C, Moskalenko M, Du T, Creson J, VanRoey MJ, Jooss K.

Cancer Immunol Immunother. 2007 Oct;56(10):1653-65. Epub 2007 Apr 5.

PMID:
17410360
24.

Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.

Li B, Lalani AS, Harding TC, Luan B, Koprivnikar K, Huan Tu G, Prell R, VanRoey MJ, Simmons AD, Jooss K.

Clin Cancer Res. 2006 Nov 15;12(22):6808-16.

25.

Efficient Tet-dependent expression of human factor IX in vivo by a new self-regulating lentiviral vector.

Vigna E, Amendola M, Benedicenti F, Simmons AD, Follenzi A, Naldini L.

Mol Ther. 2005 May;11(5):763-75.

26.

Changes in dispersal during species' range expansions.

Simmons AD, Thomas CD.

Am Nat. 2004 Sep;164(3):378-95. Epub 2004 Aug 12.

PMID:
15478092
27.

Ecological and evolutionary processes at expanding range margins.

Thomas CD, Bodsworth EJ, Wilson RJ, Simmons AD, Davies ZG, Musche M, Conradt L.

Nature. 2001 May 31;411(6837):577-81.

28.
29.

A direct interaction between EXT proteins and glycosyltransferases is defective in hereditary multiple exostoses.

Simmons AD, Musy MM, Lopes CS, Hwang LY, Yang YP, Lovett M.

Hum Mol Genet. 1999 Nov;8(12):2155-64.

PMID:
10545594
30.

Direct cDNA selection using large genomic DNA targets.

Simmons AD, Lovett M.

Methods Enzymol. 1999;303:111-26. No abstract available.

PMID:
10349642
31.

Molecular cloning and mapping of human semaphorin F from the Cri-du-chat candidate interval.

Simmons AD, Püschel AW, McPherson JD, Overhauser J, Lovett M.

Biochem Biophys Res Commun. 1998 Jan 26;242(3):685-91.

PMID:
9464278
32.

Lack of locomotor-cardiac coupling in trotting dogs.

Simmons AD, Carrier DR, Farmer CG, Gregersen CS.

Am J Physiol. 1997 Oct;273(4):R1352-60. doi: 10.1152/ajpregu.1997.273.4.R1352.

PMID:
9362299
33.

Presenilin 1 interaction in the brain with a novel member of the Armadillo family.

Zhou J, Liyanage U, Medina M, Ho C, Simmons AD, Lovett M, Kosik KS.

Neuroreport. 1997 May 27;8(8):2085-90.

PMID:
9223106
34.

Presenilin 1 interaction in the brain with a novel member of the Armadillo family.

Zhou J, Liyanage U, Medina M, Ho C, Simmons AD, Lovett M, Kosik KS.

Neuroreport. 1997 Apr 14;8(6):1489-94.

PMID:
9172160
35.
36.

Human chromosome-specific cDNA libraries: new tools for gene identification and genome annotation.

Del Mastro RG, Wang L, Simmons AD, Gallardo TD, Clines GA, Ashley JA, Hilliard CJ, Wasmuth JJ, McPherson JD, Lovett M.

Genome Res. 1995 Sep;5(2):185-94.

37.

Five novel genes from the cri-du-chat critical region isolated by direct selection.

Simmons AD, Goodart SA, Gallardo TD, Overhauser J, Lovett M.

Hum Mol Genet. 1995 Feb;4(2):295-302.

PMID:
7757083
38.

A yeast artificial chromosome contig of the critical region for cri-du-chat syndrome.

Goodart SA, Simmons AD, Grady D, Rojas K, Moyzis RK, Lovett M, Overhauser J.

Genomics. 1994 Nov 1;24(1):63-8.

PMID:
7896290
39.

myc family DNA amplification in small cell lung cancer patients' tumors and corresponding cell lines.

Johnson BE, Makuch RW, Simmons AD, Gazdar AF, Burch D, Cashell AW.

Cancer Res. 1988 Sep 15;48(18):5163-6.

40.

Dactinomycin treatment of murine lupus erythematosus. I. Renal disease and longevity.

Rudofsky UH, Urizar RE, Gabrielsen AE, Simmons AD, Olsen CT.

Lab Invest. 1978 Nov;39(5):441-8.

PMID:
153431
41.

C4 in glomerular lesions of NZB/NZW mice.

Gabrielsen AE, Simmons AD, Rudofsky UH.

Clin Exp Immunol. 1977 Feb;27(2):222-6.

42.

A comparison of repression-sensitization scores obtained by two different methods.

Simmons AD.

J Clin Psychol. 1966 Oct;22(4):465. No abstract available.

PMID:
4381924

Supplemental Content

Loading ...
Support Center